hVIVO Regulatory News (HVO)

For immediate release 7.00am: 24 May 2016

HVIVO PLC

("hVIVO" or the "Company")

David Norwood Lock-in Deed

hVIVO plc (AIM: HVO), the pioneer of human models of disease, announces that following David Norwood's retirement as a Director of hVIVO plc at Annual General Meeting on 23 May 2016, David Norwood has signed a lock-in deed with the Company with undertaking not to dispose of his hVIVO plc shareholding until after the first anniversary of the date of the deed and orderly market restriction until after the second anniversary of the date of the deed.

For further information please contact:

hVIVO plc +44 207 756 1300

Kym Denny (Chief Executive Officer)

Graham Yeatman (Chief Financial & Business Officer)

Media Enquiries +44 203 021 3933 / +44 7854 979 420

Colin Paterson (Director of Marketing, Communication and Public Relations)

Numis Securities Limited +44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Michael Burke (Corporate Broking)

Notes to Editors:

hVIVO plc ("hVIVO") is a life sciences company pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases, including flu, RSV, asthma and common cold. hVIVO has commercialised four disease models, successfully enrolled over 2,000 subjects and conducted over 40 product validation studies for a wide range of industry, government and academic clients and collaborators.